Response to Cabazitaxel Beyond 20 Cycles in A Patient with Penile Metastasis of Prostate Cancer: A Case Report

Genitourinary Cancer

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Prostate Cancer Prostatic Dis.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY

doi: 10.1038/pcan.2016.58.

Genitourinary Cancer

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

J Clin Oncol.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O

doi: 10.1200/JCO.2016.72.1068.

Breast CancerGastrointestinal CancerGenitourinary Cancer

Pulmonary metastasis as sole manifestation of relapse in previously treated localised prostate cancer: three exceptional case reports

Ecancermedicalscience.

Gago JP, Câmara G, Dionísio J, Opinião A

doi: 10.3332/ecancer.2016.645.

Genitourinary Cancer

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA

J Clin Oncol.

Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J

doi: 10.1200/JCO.2016.72.1076.

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Genitourinary Cancer

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

BJU Int.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ

doi: 10.1111/bju.13676.

Genitourinary Cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Prostate.

Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES

doi: 10.1002/pros.23955.

Genitourinary Cancer

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

J Immunother Cancer.

Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albiges L, Baciarello G, Loriot Y, Fizazi K

doi: 10.1186/s40425-017-0232-7.

Lung, Respiratory and Thoracic Cancer

Colon cancer metastasis to the thyroid gland: A case report

Int J Surg Case Rep.

Coelho MI, Albano MN, Costa Almeida CE, Reis LS, Moreira N, Almeida CMC

doi: 10.1016/

Related content

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Pulmonary metastasis as sole manifestation of relapse in previously treated localised prostate cancer: three exceptional case reports

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Colon cancer metastasis to the thyroid gland: A case report